ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2017年10月10日 10時00分
Source:
Eisai
エーザイ、中年期以降のもの忘れ改善薬「遠志（オンジ）の恵み(R)」新発売
東京, 2017年10月10日 - (JCN Newswire) - エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、中年期以降のもの忘れ改善薬「遠志の恵み(R)」（第 3 類医薬品）を本日、10 月 10 日（火）に全国の薬局・薬店、ドラッグストアにて新発売します。
「遠志の恵み」は、オンジエキスを成分とする「中年期以降の物忘れの改善」を効能・効果とする第3 類医薬品です。イトヒメハギの根を乾燥させた生薬である遠志（オンジ）には、おもに、記憶に関する機能を改善する作用が認められています。本剤について、小型化した 1 回 1 錠の生薬製剤にするとともに、錠剤をコーティングすることで生薬独特の風味を抑え、服用しやすい工夫をしています。
当社が実施した調査によると、40 代以降の 4 割以上の方が「物事や人の名前が思い出せなくなった」「同じことを何度も話してしまう」等のもの忘れを実感し、不安を感じていると回答しています。しかし、これらは加齢によるものと考えられて対処されにくいのが現状です。「遠志の恵み」は中年期以降のもの忘れが気になる方の記憶の機能を改善させます。
当社は、もの忘れや認知症に関する啓発や行政・医療・介護等の連携支援等を推進するまちづくり活動に積極的に取り組んでいます。
本製品をお届けすることで、セルフメディケーションの分野でも、もの忘れに不安を感じる皆様のベネフィット向上にさらに貢献してまいります。
本リリースの詳細は下記をご参照ください。
http://www.eisai.co.jp/news/news201758pdf.pdf
概要：エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Jul 18, 2026 00:24 JST
Hitachi and NVIDIA collaborate to advance HMAX and enable end-to-end autonomous operations through the integrated control of physical AI
Jul 17, 2026 23:35 JST
Toyota's First "BE creation" Spin-Off Begins Operations in Japan
Jul 17, 2026 23:00 JST
MHI Advances AI Infrastructure Commercialization with U.S. Deployment of 10MW-Class Chiller and MCP Development
Jul 17, 2026 22:47 JST
Noetra Launches Full-Scale R&D for Japan-Developed Multimodal Foundation Model
Jul 17, 2026 22:16 JST
Mitsubishi Motors Launches the Xforce HEV in Indonesia
Jul 17, 2026 21:47 JST
Fujitsu to explore physical AI development and implementation across industries with FANUC, Yaskawa Electric, and Kawasaki Heavy Industries integrating NVIDIA technology
Jul 17, 2026 21:05 JST
JCB Celebrates 30 Years of Trust, Honoring 70 Years of Japan-Philippines Friendship
Jul 17, 2026 10:00 JST
TANAKA Commences Operation of "TANAKA H2 Nexus", One of Japan's Largest 500 kW Pure Hydrogen Fuel Cell Power Generation Facilities
Jul 16, 2026 22:00 JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Jul 16, 2026 00:18 JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 23:51 JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 15, 2026 23:21 JST
NEC develops world's first proprietary-AI technology to rapidly generate highly detailed 3D models solely from general-purpose camera footage while automatically removing unnecessary subjects
Jul 15, 2026 22:53 JST
Hitachi Rail achieves EcoVadis platinum medal, ranking among the top 1% of companies worldwide for sustainability performance
Jul 15, 2026 22:35 JST
Anime Tokyo Station Reaches 300,000 Visitors!
Jul 15, 2026 11:00 JST
Fujitsu launches AI-driven modernization service to accelerate legacy system transformation
Jul 14, 2026 19:12 JST
Anime Tokyo Station: TV Anime "BLEACH: THE BLOOD WARFARE - The Calamity" Special Exhibition
Jul 14, 2026 11:00 JST
JCB Signs Memorandum of Understanding with Circle to Explore Collaboration Utilizing Stablecoins
Jul 14, 2026 10:00 JST
Mitsubishi Power Receives Contract to Supply Boilers for Fuel Conversion Work at Existing Thermal Power Plants in Saudi Arabia
Jul 14, 2026 00:58 JST
Fujitsu developed an AI Agent to collaborate with store managers for AEON Food Style's strategic store operations
Jul 14, 2026 00:38 JST
More Latest Release >>
Related Release
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
7/18/2026 12:24:00 AM JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
7/16/2026 12:18:00 AM JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
7/15/2026 11:51:00 PM JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
7/15/2026 11:21:00 PM JST
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
7/14/2026 12:06:00 AM JST
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
7/2/2026 10:45:00 PM JST
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
7/2/2026 10:01:00 PM JST
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
6/17/2026 1:28:00 PM JST
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
5/22/2026 12:23:00 AM JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
4/21/2026 8:52:00 PM JST
More Press release >>